GET DAILY SIGNALSWhy Is Quantum-Si (QSI) Stock Down -8.04% Today?
Key Takeaways
- QSI shares fell roughly 8.04% to about $1.03, extending Friday's steep selloff from a prior close of $1.12.
- The primary catalyst was a fresh analyst downgrade, with Wall Street Zen cutting the stock from "hold" to "sell."
- Secondary pressure came from a broad biotechnology-sector selloff that has hit speculative, pre-revenue life-sciences names hard.
- The decline also reflects profit-taking after a Proteus-driven rally pushed the stock to an 11-month high in mid-October.
- Traders are now watching the upcoming third-quarter earnings report on November 5 and the company's Proteus development milestones.
Opening Summary
Quantum-Si Incorporated (QSI), a Branford, Connecticut-based proteomics technology company that develops single-molecule protein sequencing instruments, extended its losses in Monday's session. The stock fell approximately 8.04% to around $1.03, down from Friday's closing price of $1.12. The decline came on the heels of an already sharp 14.5% drop in the prior session, as a fresh sell-side downgrade compounded a wider pullback across the biotechnology sector.
Analyst Downgrade Adds Selling Pressure
The most direct catalyst for Monday's move was a downgrade from Wall Street Zen, which lowered its rating on QSI from "hold" to "sell." For a speculative, development-stage company whose valuation is largely tied to future product launches, rating changes carry outsized weight, particularly when they follow a rapid price run-up. The downgrade reinforced concerns about execution risk and near-term commercial traction, prompting investors to lock in recent gains.
Broad Biotechnology Sector Selloff
The stock's decline also reflects broader weakness across the biotechnology complex. The Nasdaq Biotechnology Index fell sharply in Friday's session, with a wide range of development-stage and genomics names trading lower. Quantum-Si's shares were among the sector's notable decliners, underscoring how risk appetite toward pre-revenue life-sciences companies has cooled. When sector-wide sentiment deteriorates, high-beta names with limited near-term revenue tend to experience amplified moves.
Profit-Taking After a Proteus-Fueled Rally
The pullback follows a strong rally earlier in October. On October 8, Quantum-Si announced that its next-generation Proteus platform had demonstrated detection of 19 amino acids, one short of the full set of 20 needed for complete protein sequencing. The news propelled the stock higher, and shares climbed to an 11-month high above $1.40 by mid-October. With those gains now partially unwound, Monday's selling reflects a classic giveback of a sentiment-driven spike as momentum cooled.
Market Context and Trading Activity
Trading activity has been notably heavy relative to the stock's typical average volume, consistent with the elevated participation seen during Friday's decline. The move has diverged from the action in broader large-cap benchmarks, which have been comparatively stable, highlighting the stock-specific and sector-specific nature of the selling. Despite the decline, QSI remains above its 50-day and 200-day moving averages, a reminder that it is still trading well off its 52-week lows even as it surrenders its October gains. The stock's elevated beta and meaningful short interest have also contributed to outsized day-to-day volatility.
What Comes Next for QSI
Investors' attention now shifts to Quantum-Si's third-quarter 2026 business update and financial results, scheduled for November 5, 2026. Management commentary on the Proteus commercial launch timeline, which has already been pushed to the second quarter of 2027, will be closely scrutinized. The company has also targeted the demonstration of all 20 standard amino acids by the end of 2026, a milestone that could refocus sentiment. Risks include continued technology and manufacturing execution uncertainty, persistent cash burn, potential future dilution, and a still-weak commercial revenue base. Any further deterioration in biotechnology-sector risk appetite could also keep pressure on the shares.
Trending AI Robots
For traders seeking a more systematic approach to volatile names like QSI, Tickeron's Trending AI Robots page offers a curated view of AI-driven trading strategies. Tickeron provides hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in this section. These bots vary by strategy, timeframe, performance metrics, and traded symbols, allowing users to explore approaches tailored to different market environments. Explore the Trending AI Robots page to see which strategies are currently leading.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
QSI's RSI Indicator peaks and leaves overbought zone
The 10-day RSI Indicator for QSI moved out of overbought territory on October 12, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 instances where the indicator moved out of the overbought zone. In 24 of the 26 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 43 of 50 cases where QSI's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 86%.
The Momentum Indicator moved below the 0 level on October 15, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on QSI as a result. In 86 of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for QSI turned negative on October 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 40 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where QSI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
QSI broke above its upper Bollinger Band on September 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
QSI moved above its 50-day moving average on September 24, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for QSI crossed bullishly above the 50-day moving average on September 29, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +44.86% 3-day Advance, the price is estimated to grow further. Considering data from situations where QSI advanced for three days, in 156 of 197 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
The Aroon Indicator entered an Uptrend today. In 94 of 122 cases where QSI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 77%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 33 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.360) is normal, around the industry mean (2.949). P/E Ratio (-2.435) is within average values for comparable stocks, (2.438). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (100.000) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. QSI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 63 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. QSI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices
Advertisement